TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 89,600 shares, a growth of 71.0% from the December 15th total of 52,400 shares. Based on an average daily volume of 57,900 shares, the short-interest ratio is currently 1.5 days. Approximately 12.9% of the shares of the stock are sold short.

Institutional Trading of TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management boosted its stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the SEC.

TransCode Therapeutics Price Performance

Shares of TransCode Therapeutics stock traded down $0.17 on Wednesday, hitting $3.19. The company’s stock had a trading volume of 101,982 shares, compared to its average volume of 122,352. TransCode Therapeutics has a 52-week low of $2.66 and a 52-week high of $152.79. The firm has a fifty day moving average price of $161.96 and a 200-day moving average price of $397.64.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright boosted their target price on TransCode Therapeutics from $3.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.